{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000187","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.019582+00:00","generated_at":"2026-06-08T05:28:40.524962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa Q3 2023 net loss $38.6M; cash $281.3M, SerpinPC data at ASH","bullets":["Cash and investments $281.3M as of Sep 30, 2023; expected to fund operations into 2026.","Net loss of $38.6M vs $53.9M in Q3 2022; R&D expense $28.2M, down 23% YoY.","SerpinPC Phase 2a Part 5 data accepted for ASH poster Dec 10; PRESent-2 and PRESent-3 registrational studies ongoing.","ORX750 (OX2R agonist) preclinical data support best-in-class profile for narcolepsy; IND-enabling studies underway, clinical proof-of-concept data planned for 2024.","LockBody platform: LB101 (PD-L1xCD47) Phase 1/2a ongoing; LB206 (PD-L1xCD3) development candidate selected in August."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000187","json":"https://secwatch.observer/filing/0001847903-23-000187.json","markdown":"https://secwatch.observer/filing/0001847903-23-000187.md","text":"https://secwatch.observer/filing/0001847903-23-000187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/0001847903-23-000187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/cnta-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:28:40.524962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"786a07682759670065b2a4119f215863473422bb","claim":"Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2023 results: net income $38.6 million.","evidence_excerpt":"Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/0001847903-23-000187-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$38.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}